文献速递眼底病与葡萄膜炎青光眼

DARC技术检测视网膜细胞应激与凋亡:从实验室到临床的进展

Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic.
PubMed 文献 · Prog Retin Eye Res · 2021-06-05

DARC是一种利用荧光标记膜联蛋白A5(ANX776)检测活体眼内应激和凋亡细胞的视网膜成像技术,已从基础研究推进至2期临床试验。静脉注射ANX776在129例患者中安全且耐受良好,结果提示DARC结合AI算法可预测青光眼和AMD的疾病活动。本文还报告了DARC在地图样萎缩(GA)预测中的新分析,但需更大规模研究验证其生物标志物潜力。

要点

  • DARC使用ANX776识别活体眼内应激和凋亡细胞。
  • 静脉ANX776在129例患者中安全且耐受良好。
  • DARC联合AI算法可能预测青光眼和AMD疾病活动。

核心结论

  • DARC技术有潜力作为生物标志物,但需更大规模临床研究验证后才能考虑作为诊断工具。

研究设计与样本

  • 本文为综述,描述DARC从实验室研究到2期临床试验的进展。
  • DARC在临床前青光眼和视神经病变模型中进行测试,也在AMD、阿尔茨海默病、帕金森病和糖尿病模型中进行研究。

主要发现

  • 静脉注射ANX776在129例患者中安全且耐受良好,包括1期16例和2期113例。
  • 青光眼和AMD患者的结果提示DARC结合AI辅助算法可预测疾病活动。
  • 本文报告了DARC在地图样萎缩(GA)预测中的新分析。

临床怎么用

  • DARC可能作为生物标志物用于预测青光眼和AMD的疾病活动。
  • 鼻内给药比静脉给药创伤更小,未来可能提高其作为筛查工具的可接受性。

局限性

  • 需要进一步研究验证这些发现。
  • 在考虑作为诊断工具之前,需要进行更大规模的临床研究。
  • 技术转化面临假设、潜在挑战和监管障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DARC (Detection of Apoptosing Retinal Cells) is a retinal imaging technology that has been developed within the last 2 decades from basic laboratory science to Phase 2 clinical trials. It uses ANX776 (fluorescently labelled Annexin A5) to identify stressed and apoptotic cells in the living eye. During its development, DARC has undergone biochemistry optimisation, scale-up and GMP manufacture and extensive preclinical evaluation. Initially tested in preclinical glaucoma and optic neuropathy models, it has also been investigated in AMD, Alzheimer's, Parkinson's and Diabetic models, and used to assess efficacy of therapies. Progression to clinical trials has not been speedy. Intravenous ANX776 has to date been found to be safe and well-tolerated in 129 patients, including 16 from Phase 1 and 113 from Phase 2. Results on glaucoma and AMD patients have been recently published, and suggest DARC with an AI-aided algorithm can be used to predict disease activity. New analyses of DARC in GA (Geographic Atrophy) prediction are reported here. Although further studies are needed to validate these findings, it appears there is potential for the technology to be used as a biomarker. Much larger clinical studies will be needed before it can be considered as a diagnostic, although the relatively non-invasive nature of the nasal as opposed to intravenous administration would widen its acceptability in the future as a screening tool. This review describes DARC development and its progression into Phase 2 clinical trials from lab-based research. It discusses hypotheses, potential challenges, and regulatory hurdles in translating technology.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Cordeiro MF, Hill D, Patel R, et al. Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic. Prog Retin Eye Res. 2021. PMID: 34102318. doi:10.1016/j.preteyeres.2021.100976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。